News | December 07, 2023
Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Subscribe To Our Newsletter & Stay Updated
